Association Between Obesity and Biomarkers of Inflammation and Metabolism with Cancer Mortality in a Prospective Cohort Study

Overview

Journal Metabolism

Specialty Endocrinology

Date 2019 Feb 26

PMID 30802456

Citations 13

Authors

Daniel T Dibaba

Suzanne E Judd

Susan C Gilchrist

Mary Cushman

Maria Pisu

Monika Safford

Tomi Akinyemiju

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the association between biomarkers of inflammation and metabolic dysregulation and cancer mortality by obesity status.

Methods: Data from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort was used to examine the associations between baseline biomarkers of inflammation (IL-6, IL-8, IL-10, and CRP) and metabolism (adiponectin, resisting and lipoprotein (a)) with cancer mortality among 1822 participants cancer-free at baseline. Weighted Cox proportional hazard regression with the robust sandwich method was used to estimate the hazard ratios and 95% confidence intervals (CIs) adjusting for baseline covariates and stratified by BMI (normal, overweight/obese) given the significant interaction between biomarkers and BMI (p < 0.1).

Results: During a mean follow-up of 8 years, there were statistically significant associations between cancer mortality and being in the highest vs. lowest tertile of IL-6 (HR: 5.3; 95% CI: 1.6, 17.8), CRP (HR: 3.4; 95% CI: 1.0, 11.2) and resistin (HR: 3.7; 95% CI: 1.2, 11.2) among participants with normal BMI. IL-6 was also associated with a 3-fold (HR: 3.5; 95% CI: 1.5, 8.1) increased risk of cancer mortality among participants with overweight/obesity; however, neither CRP nor resistin was significantly associated with cancer mortality in this group.

Conclusions: Higher baseline inflammatory and metabolic biomarkers were associated with significantly increased risk of cancer mortality after adjusting for baseline risk factors and the associations varied by BMI. Cancer patients may benefit from interventions that modulate inflammatory and metabolic biomarkers.

Citing Articles

Analysis of dietary inflammatory potential and mortality in cancer survivors using NHANES data.

Wu Y, Yi J, Zhang Q Front Nutr. 2024; 11:1467259.

PMID: 39346654 PMC: 11427406. DOI: 10.3389/fnut.2024.1467259.

Development and Internal Validation of a Prediction Model for Nasopharyngeal Carcinoma: Using BMI and Inflammatory Response for Deciding Sequence of Chemotherapy.

Setakornnukul J, Petsuksiri J, Chaysiri P, Danchaivijitr P, Ngamphaiboon N, Thephamongkhol K JCO Glob Oncol. 2024; 10:e2300119.

PMID: 38359375 PMC: 10881098. DOI: 10.1200/GO.23.00119.

Diet quality and lung cancer incidence in a low-income population in the United States.

Munro H, Yu D, Zheng W, Blot W, Cai Q, Shrubsole M Br J Cancer. 2023; 129(4):626-635.

PMID: 37400676 PMC: 10421925. DOI: 10.1038/s41416-023-02342-7.

Unveiling the MUFA-Cancer Connection: Insights from Endogenous and Exogenous Perspectives.

Guo Z, Bergeron K, Lingrand M, Mounier C Int J Mol Sci. 2023; 24(12).

PMID: 37373069 PMC: 10298224. DOI: 10.3390/ijms24129921.

Obesity, the Adipose Organ and Cancer in Humans: Association or Causation?.

Trevellin E, Bettini S, Pilatone A, Vettor R, Milan G Biomedicines. 2023; 11(5).

PMID: 37238992 PMC: 10215824. DOI: 10.3390/biomedicines11051319.

References

Lin S, Gan Z, Han K, Yao Y, Min D . Interleukin-6 as a prognostic marker for breast cancer: a meta-analysis. Tumori. 2015; 101(5):535-41. DOI: 10.5301/tj.5000357. View

Ko Y, Kwon Y, Kim K, Choi H, Chun S, Yoon H . High-sensitivity C-reactive protein levels and cancer mortality. Cancer Epidemiol Biomarkers Prev. 2012; 21(11):2076-86. DOI: 10.1158/1055-9965.EPI-12-0611. View

Yang M, Kenfield S, Van Blarigan E, Batista J, Sesso H, Ma J . Dietary patterns after prostate cancer diagnosis in relation to disease-specific and total mortality. Cancer Prev Res (Phila). 2015; 8(6):545-51. PMC: 4452958. DOI: 10.1158/1940-6207.CAPR-14-0442. View

Enewold L, Mechanic L, Bowman E, Zheng Y, Yu Z, Trivers G . Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev. 2009; 18(1):215-22. PMC: 2790156. DOI: 10.1158/1055-9965.EPI-08-0705. View

Iyengar N, Gucalp A, Dannenberg A, Hudis C . Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation. J Clin Oncol. 2016; 34(35):4270-4276. PMC: 5562428. DOI: 10.1200/JCO.2016.67.4283. View

Hojbjerre L, Sonne M, Alibegovic A, Nielsen N, Dela F, Vaag A . Impact of physical inactivity on adipose tissue low-grade inflammation in first-degree relatives of type 2 diabetic patients. Diabetes Care. 2011; 34(10):2265-72. PMC: 3177724. DOI: 10.2337/dc11-0631. View

Hannan F, Culligan K . Human resistin and the RELM of Inflammation in diabesity. Diabetol Metab Syndr. 2015; 7:54. PMC: 4474570. DOI: 10.1186/s13098-015-0050-3. View

Kolb R, Sutterwala F, Zhang W . Obesity and cancer: inflammation bridges the two. Curr Opin Pharmacol. 2016; 29:77-89. PMC: 4992602. DOI: 10.1016/j.coph.2016.07.005. View

Jaggers J, Sui X, Hooker S, LaMonte M, Matthews C, Hand G . Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer. 2009; 45(10):1831-8. PMC: 2700189. DOI: 10.1016/j.ejca.2009.01.031. View

10.

Colantonio L, Gamboa C, Kleindorfer D, Carson A, Howard V, Muntner P . Stroke symptoms and risk for incident coronary heart disease in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Int J Cardiol. 2016; 220:122-8. PMC: 4983497. DOI: 10.1016/j.ijcard.2016.06.030. View

11.

Ferrari P, Licaj I, Muller D, Andersen P, Johansson M, Boeing H . Lifetime alcohol use and overall and cause-specific mortality in the European Prospective Investigation into Cancer and nutrition (EPIC) study. BMJ Open. 2014; 4(7):e005245. PMC: 4091394. DOI: 10.1136/bmjopen-2014-005245. View

12.

Lund Haheim L, Wisloff T, Holme I, Nafstad P . Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol. 2006; 164(8):769-74. DOI: 10.1093/aje/kwj284. View

13.

Chong D, Mehta R, Song M, Kedrin D, Meyerhardt J, Ng K . Prediagnostic Plasma Adiponectin and Survival among Patients with Colorectal Cancer. Cancer Prev Res (Phila). 2015; 8(12):1138-45. PMC: 4670783. DOI: 10.1158/1940-6207.CAPR-15-0175. View

14.

Jamaluddin M, Weakley S, Yao Q, Chen C . Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol. 2011; 165(3):622-32. PMC: 3315035. DOI: 10.1111/j.1476-5381.2011.01369.x. View

15.

Li Y, Zhong X, Cheng G, Zhao C, Zhang L, Hong Y . Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis. Atherosclerosis. 2017; 259:75-82. DOI: 10.1016/j.atherosclerosis.2017.02.003. View

16.

Orlich M, Singh P, Sabate J, Fan J, Sveen L, Bennett H . Vegetarian dietary patterns and the risk of colorectal cancers. JAMA Intern Med. 2015; 175(5):767-76. PMC: 4420687. DOI: 10.1001/jamainternmed.2015.59. View

17.

Lippitz B, Harris R . Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis. Oncoimmunology. 2016; 5(5):e1093722. PMC: 4910721. DOI: 10.1080/2162402X.2015.1093722. View

18.

Gilbert C, Slingerland J . Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annu Rev Med. 2012; 64:45-57. DOI: 10.1146/annurev-med-121211-091527. View

19.

Gathirua-Mwangi W, Monahan P, Murage M, Zhang J . Metabolic syndrome and total cancer mortality in the Third National Health and Nutrition Examination Survey. Cancer Causes Control. 2017; 28(2):127-136. PMC: 5308139. DOI: 10.1007/s10552-016-0843-1. View

20.

Trabert B, Eldridge R, Pfeiffer R, Shiels M, Kemp T, Guillemette C . Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Int J Cancer. 2016; 140(3):600-610. PMC: 5159268. DOI: 10.1002/ijc.30478. View